Kara L. O'Brien

TL;DR: The construction of three novel rAd vector systems from Ad26, Ad48, and Ad50 are described and a detailed comparison of multiple rAd vectors from subgroups B and D is reported, which substantially expand the portfolio of rare serotype r adenovirus serotype vectors that may prove useful as vaccine vectors for the developing world.

TL;DR: It is demonstrated that durable partial immune control of a pathogenic SIV challenge for more than 500 days can be achieved by a T-cell-based vaccine in Mamu-A*01-negative rhesus monkeys in the absence of a homologous Env antigen.

TL;DR: It is shown that mosaic HIV-1 Gag, Pol and Env antigens expressed by recombinant, replication-incompetent adenovirus serotype 26 vectors markedly augmented both the breadth and depth without compromising the magnitude of antigen-specific T lymphocyte responses in rhesus monkeys.

TL;DR: Findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study.

TL;DR: A clear age dependence of Ad5-specific neutralizing antibody titers is observed, which will help to guide the development of Ad vector-based vaccines for human immunodeficiency virus type 1 and other pathogens.